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Abstract
Background: Alzheimer’s disease (AD) is a severe neuroinflammatory disease. CD4+Foxp3+ regulatory T cells (Tregs)
modulate various inflammatory diseases via suppressing Th cell activation. There are increasing evidences that Tregs
have beneficial roles in neurodegenerative diseases. Previously, we found the population of Treg cells was
significantly increased by bee venom phospholipase A2 (bvPLA2) treatment in vivo and in vitro.
Methods: To examine the effects of bvPLA2 on AD, bvPLA2 was administered to 3xTg-AD mice, mouse model of
Alzheimer’s disease. The levels of amyloid beta (Aβ) deposits in the hippocampus, glucose metabolism in the brain,
microglia activation, and CD4+ T cell infiltration were analyzed to evaluate the neuroprotective effect of bvPLA2.
Results: bvPLA2 treatment significantly enhanced the cognitive function of the 3xTg-AD mice and increased
glucose metabolism, as assessed with 18F-2 fluoro-2-deoxy-D-glucose ([F-18] FDG) positron emission tomography
(PET). The levels of Aβ deposits in the hippocampus were dramatically decreased by bvPLA2 treatment. This
neuroprotective effect of bvPLA2 was associated with microglial deactivation and reduction in CD4+ T cell
infiltration. Interestingly, the neuroprotective effects of bvPLA2 were abolished in Treg-depleted mice.
Conclusions: The present studies strongly suggest that the increase of Treg population by bvPLA2 treatment
might inhibit progression of AD in the 3xTg AD mice.
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Background
Alzheimer’s disease (AD) is a degenerative disease of the
central nervous system. AD is pathologically character-
ized by extracellular senile plaques, intracellular neuro-
fibrillary tangles, and a reduction of neurons in the
cerebral cortex and hippocampus. The clinical features
of AD are loss of memory and cognitive and behavioral
disorders [1]. AD is one of the most common types of
dementia, but its etiology and pathogenesis remain un-
clear. At present, various pathological processes are
known to be involved in AD. However, the amyloid cas-
cade hypothesis and the amyloid beta (Aβ) toxicity
hypothesis have dominated research for decades. And
the deposition of Aβ peptide in the brain is considered a
central event in AD [2, 3]. Although the etiology of AD
is unknown, many evidences suggest that inflammatory
responses play a crucial role in its pathogenesis [4, 5].
Inflammatory processes that are marked by activated
microglia and astrocytes, some of which co-localize to
plaques and tangles have long been hypothesized to con-
tribute to AD pathogenesis [6]. Activated microglia have
been found in the brains of AD patients with dementia
and or patients with mild cognitive impairment [7, 8].
Microglia, the resident immune cells of the central ner-
vous system, are activated to phagocytize Aβ [9], but the
impaired clearance or reuptake of Aβ results in the
release of inflammatory cytokines that cause neuroin-
flammation [10]. Therefore, microglial activation might
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contribute to the deposition of Aβ and the progression
of AD [11].
At present, there is absolutely no significant treatment
for AD. The current mainstays of treatment for cognitive
loss related to AD are muscarinic or nicotinic receptor
ligands and acetylcholinesterase (AChE) inhibitors [12].
However, these drugs have undesirable side effects that
include diarrhea, nausea, vomiting, muscle cramps, sed-
ation, and bradycardia [13]. Despite many years of inten-
sive research, the mechanisms that trigger the disease
remain uncertain, and there is currently no promising
treatment [14]. Accordingly, the identification of effect-
ive and safe treatments with clear pharmacological
mechanisms is urgently needed.
In the present study, we used a triple-transgenic model
(3xTg-AD mouse) that is unique among previous models
because it expresses three dementia-related transgenes,
i.e., namely APPSwe, PS1M146V, and tauP301L and exhibits
a clear age-dependent onset of AD neuropathology [15].
Extracellular Aβ deposits have been shown to be appar-
ent at 6 months and are predominantly located in the
hippocampus and frontal cortex [16, 17].
Phospholipase A2 (PLA2) is an enzyme that catalyzes
the hydrolysis of the sn-2 fatty acyl bond of membrane
phospholipids to produce free fatty acids and lysopho-
spholipids [18, 19]. PLA2 is present in various species and
has been categorized into three broad classes based on
cellular distribution: a secreted or extracellular type
(sPLA2), a cytosolic or intracellular type (cPLA2), and a
Ca2+-independent PLA2. In addition to mammals, sPLA2
is present in the venom of snakes, bees, cnidarians, and
scorpions. sPLA2 plays important roles in a wide range of
cellular responses, including phospholipid metabolism,
signal transduction, and the initiation and regulation of in-
flammatory and immune responses [20–23].
It has previously been reported that bee venom pos-
sesses therapeutic effects in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s
disease model that are mediated via the modulating of
Treg populations. And we also reported that bvPLA2
treatment induce Treg population in vivo and in vitro
[24]. In the present study, we examined the effects of
PLA2 from bee venom (bvPLA2) on the learning and
memory abilities of 3xTg-AD mice using the Morris
water maze. We further sought to determine whether
bvPLA2 decreases Aβ in the 3xTg mouse model of AD.
We also demonstrated that the neuroprotective effects
of bvPLA2 were associated with the suppression of
microglial activation via the modulation of peripheral
immune tolerance by Tregs. Furthermore, we examined
brain activity using positron emission tomography (PET)
with 18F-2 fluoro-2-deoxy-D-glucose ([F-18] FDG),




bvPLA2 (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in sterile phosphate-buffered saline (PBS) and
kept at −20 °C until use. The 3xTg AD mice harboring a
mutant APP (KM670/671NL), which is a human mutant
PS1 (M146V) knock-in, and tau (P301L) transgenes
(B6;129-Psen1tm1Mpm Tg(APPSwe, tauP301L)1Lfa/J) [15]
were purchased from Jackson Laboratory (Bar Harbor,
ME, USA). Non-transgenic littermates were used as wild
type (WT) controls. The animal procedures were ap-
proved by the University of Kyung Hee Institutional
Animal Care and Usage Committee (KHUASP(SE)-13-
015) and were in accordance with the Guide for the Care
and Use of Laboratory Animals of the National Institutes
of Health. All animals were maintained in a pathogen-
free environment on a 12-h light/dark cycle and had
access to food and water ad libitum. The mice were ran-
domly assigned to five groups as follows: (1) a PBS-
treated WT group (WT, n = 6); (2) a PBS-treated 3xTg
group (3xTg, n = 5); (3) a 0.6 mg/kg donepezil-treated
3xTg group (3xTg+donepezil, n = 6); (4) a 0.2 mg/kg
bvPLA2-treated 3xTg group (3xTg+bvPLA2 0.2, n = 6);
and (5) a 1 mg/kg bvPLA2-treated 3xTg group (3xTg+
bvPLA2 1, n = 4). Donepezil was used as a positive con-
trol and was purchased from Sigma (Sigma, St. Louis,
MO, USA). Beginning at 3 months of age, PBS, bvPLA2,
or donepezil was intraperitoneally administered for
3 months once per week until they were 6 months old.
For the Treg depletion, anti-mouse CD25 rat IgG (anti-
CD25, clone PC61) antibodies were generated in-house
from hybridomas obtained from the American Type
Culture Collection (Manassas, VA, USA). The mice re-
ceived doses of 1 mg/kg of anti-CD25 rat IgG or normal
anti-rat IgG1 once per week for 3 months until they
were 6 months old. The efficacy of the CD4+ CD25+
Foxp3+ Treg cell depletion was determined by flow cy-
tometry (FACS, FACSCalibur, BD Biosciences, San Jose,
CA, USA) using anti-CD25-PE, anti-CD4-FITC, and
anti-Foxp3-Cy5 PE (eBiosciences).
Morris water maze test
A modified version of the water maze procedure re-
ported by Morris was used [25]. The water maze was a
circular pool of 90 cm in diameter that was constructed
of fiberglass. The pool contained water that was main-
tained at a temperature of 22 ± 2 °C and contained 1 kg
of powdered skim milk to make the water opaque. Dur-
ing the water maze testing, a platform (6 cm in diam-
eter) was fixed at 1 cm below the surface of the water at
an identical location within the pool. The pool was
surrounded by different extra-maze cues. Each trial was
initiated at one of the different starting positions, and
the swimming path of each mouse was recorded with a
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video camera connected to a video recorder and a tracking
device (S-MART, Pan-Lab, Spain). All mice were subjected
to four trials per day at intervals of 15 min for four con-
secutive days followed by 1 day of probe trials on the fifth
day. The trials were considered to be completed when the
mice found the hidden platform or the escape latency
reached 60 s. For the probe trials, the platform was re-
moved from the pool, and the mice were put in the pool for
60 s to search for the previous location of the platform. The
memory retention was measured by the percentage of time
spent searching for the platform in the training quadrant.
Tissue preparation and immunohistochemical staining
The mice were transcardially perfused with saline solution
with 0.5 % sodium nitrate and heparin (10 U/ml) and then
fixed with 4 % paraformaldehyde (PFA) in 0.1 M phosphate
buffer (PB). Each brain was dissected from the skull, post-
fixed overnight in 4 % PFA at 4 °C, stored in a 30 % sucrose
solution at 4 °C until it sank, and frozen-sectioned on a
sliding microtome into 30-μm-thick coronal sections. All of
the sections were processed for immunohistochemical
(IHC) staining as described previously [26]. The brain
sections were washed with PBS and incubated overnight at
room temperature with primary antibody. The next day,
the brain sections were washed with PBS with 0.5 % bovine
serum albumin (BSA), incubated with the biotinylated
secondary antibody, and processed with an avidin-biotin
complex kit (Vectastain ABC kit; Vector Laboratories,
Burlingame, CA, USA). The bound anti-serum was visual-
ized by incubation with 0.05 % diaminobenzidine-HCl
(DAB) and 0.003 % hydrogen peroxide in 0.1 M PB. The
DAB reaction was stopped by washing the slide section
with 0.1 M PB. The primary antibodies that were used were
directed against Aβ (1:100; Abcam, Cambridge, MA, USA),
CD11b (1:200; Serotec, Oxford, UK), and CD4 (1:200;
Serotec). The tissue sections were then mounted on
gelatin-coated slides and observed under a bright-field
microscope (Nikon, Tokyo, Japan).
Flow cytometric analysis
After the behavioral tests, single-cell suspensions of sple-
nocytes were stained with fluorescently tagged CD4,
CD25, and Foxp3 (eBiosciences, San Diego, CA, USA) in
accordance with the manufacturer’s instructions. All FACS
data were acquired using a FACSCalibur flow cytometer
(BD Biosciences) and analyzed using CellQuest Pro (BD
Biosciences).
Immunohistochemistry and quantification
Coronal sections of the hippocampus, starting rostrally
from anteroposterior −2.1 mm and continuing to antero-
posterior −4.5 mm relative to bregma, were collected.
The numbers of CD11b-positive microglia/macrophages
and CD4+ T cells in the hippocampi stained with single-
label immunohistochemistry were counted under a ×400
objective (250 μm) using a light microscope (Nikon).
Densitometry analysis
The coronal sections of the hippocampus, starting rostrally
from anteroposterior −2.1 mm and continuing to antero-
posterior −4.5 mm relative to bregma, were examined at
×10 magnification using the IMAGE PRO PLUS system
(version 4.0; Media Cybernetics, Silver Spring, MD, USA)
on a computer attached to a light microscope (Zeiss
Axioskop, Oberkochen, Germany) that was interfaced
with a charge-coupled device video camera (Kodak Mega
Plus model 1.4 I). To determine the density of the Aβ-
immunoreactive, CD11b-positive microglia/macrophages,
and CD4+ T cells staining in the hippocampus, a square
frame of 500 × 500 μm was placed on the dorsal part of
the hippocampus. A second square frame of 200 × 200 μm
was placed in the region of the corpus callosum to meas-
ure the background value. To control for variations in
background illumination, the average of the background
density readings from the corpus callosum was subtracted
from the average of the density readings from the hippo-
campus for each section.
[F-18] FDG micro-PET scan
All the mice were fasted for 12–15 h before the experi-
ments to enhance the [F-18] FDG uptake in the brain
[27]. Before the [F-18] FDG injection, all mice were put
on a heating pad in a cage and warmed for at least
30 min. The temperatures of the cages were maintained at
30 °C throughout the uptake period in accordance with an
optimized [F-18] FDG uptake protocol [28]. [F-18] FDG
(500 μCi/100 g body weight) was injected through a tail
vein, and the mice were anesthetized with 2 % isoflurane
in 100 % oxygen (Forane solution; ChoongWae Pharma,
Seoul, Korea). For the PET imaging, a Siemens Inveon
PET scanner (Siemens Medical Solutions, Malvern, PA,
USA) was used throughout the study. The transverse reso-
lution was used was <1.8 mm at the center [29, 30].
Transmission PET data were acquired for 15 min using a
Co-57 point source with an energy window of 120–
125 keV. One mCi of [F-18] FDG was injected. Thirty min
after injection of 1 mCi of [F-18] FDG, which period
allowing adequate time for tracer uptake, emission PET
data during 30 min were acquired within an energy win-
dow of 350-650 keV. The emission list-mode PET data
were sorted into 3D sinograms and reconstructed using
three DRP methods. The pixel size of the reconstructed
images was 0.15 × 0.15 × 0.79 mm3. Attenuation and scat-
ter corrections were performed for all of the datasets.
Voxel-based statistical analysis
Voxel-based statistical analysis was performed to com-
pare the cerebral glucose metabolisms of the datasets of
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the different groups. The procedure used for the statis-
tical parametric mapping (SPM) analysis of the animal
PET data has previously been described [31]. Briefly, for
efficient spatial normalization, only the brain region was
extracted. A study-specific template was then con-
structed using all of the datasets. The PET data were
spatially normalized onto a mouse brain template and
smoothed using a Gaussian kernel. Count normalization
was performed. A voxel-wise t test between the groups’
datasets was performed using the Statistical Parametric
Mapping 5 program (P < 0.05, K > 50) (Table 1).
Statistical analysis
Statistical comparisons for the behavioral and histo-
chemical studies were performed with one-way ANO-
VAs followed by Tukey’s post hoc tests. All values are
expressed as the mean ± the SEM, and Prism 5.01 soft-
ware (GraphPad Software Inc., San Diego, CA, USA) for
Windows was used for the statistical analyses. The sig-
nificance level was set at P < 0.05.
Results
Effect of bvPLA2 treatment on the body weights of the mice
The body weights of the wild type (WT), donepezil-
treated, bvPLA2-treated, and vehicle-treated 3xTg AD
mice were measured every week during the 3-month
treatment (Fig. 1a). There were no obvious effects of
bvPLA2-treatment (3 to 6 months of age) on the body
weights compared to the vehicle-treated 3xTg AD mice.
In contrast, the donepezil treatment group exhibited sig-
nificantly decreased body weight compared to the
vehicle-treated 3xTg AD group.
bvPLA2 reverses the spatial learning deficits of 6-month-
old 3xTg-AD mice
The latencies to escape onto the hidden platform during
the acquisition trials of the water maze were recorded.
The escape latencies differed between the groups when
the results were averaged over all sessions. The latencies
to find the hidden platform of the WT, donepezil, and
bvPLA2 (0.2 and 1 mg/kg) groups were significantly
shorter than those of the 3xTg AD group (Fig. 1b).
The total times spent in the quadrant that previously
contained the platform were used to evaluate the spatial
performances of the mice the during retention trials.
The results of the retention tests on the fifth day are
depicted in Fig. 1c. The bvPLA2-treated group (0.2 mg/kg)
exhibited a significant increase (P < 0.05) in retention time
compared to the 3xTg AD group (Fig. 1c).
Effects of bvPLA2 on Aβ pathology in the 3xTg-AD mice
In 3xTg-AD mice, Aβ deposits are present in the hippo-
campus by 6 months of age [16, 17]. Quantifications of
the Aβ burden revealed significantly increased burden in
the hippocampal CA1 and CA3 regions of 3xTg AD
group at the age of 6 months compared to the age-
matched WT group (100 ± 4.72, P < 0.001, 100 ± 7.6, P <
0.001, respectively, Fig. 2c, d). Compared to the vehicle-
treated 3xTg AD group, the Aβ burden in CA1 was dra-
matically decreased following bvPLA2 treatment (0.2 mg
group 69.7 ± 5.84 %, P < 0.001 and 1 mg group 54.2 ±
4.79 %, P < 0.001, Fig. 2a, c). Similarly, donepezil treat-
ment also decreased the Aβ burden in the CA1 region
(60.9 ± 5.84, P < 0.001, Fig. 2). In contrast, only the CA3
regions of the bvPLA2-treated groups exhibited signifi-
cant decreases in the amounts of Aβ burden (0.2 mg
group 76.4 ± 5.42 %, P < 0.05 and 1 mg group 70.3 ±
3.72 %, P < 0.01, Fig. 2d), and there were no significant
differences between the donepezil treatment group and
the vehicle-treated 3xTg AD group.
Changes in brain glucose metabolism
In vivo analyses of the brain glucose metabolism of live
mice were performed using positron emission tomography.
FDG-PET imaging scans indicated differences in the cere-
bral glucose metabolism rates from the hippocampi to the
prefrontal cortices between the WT and 3xTg-AD groups
(Fig. 3a), the 3xTg-AD and 3xTg-AD+donepezil groups
(Fig. 3b), and the 3xTg-AD and 3xTg-AD+bvPLA2 groups
(Fig. 3c). The SPM analysis revealed that the glucose
metabolism in the diencephalon of the WT mice was sig-
nificantly increased compared to that of the 3xTg-AD mice
(P < 0.05). The glucose metabolism of the donepezil treat-
ment group in the cortex was significantly increased
compared to that of the 3xTg-AD group (P < 0.05).
The glucose metabolism of the bvPLA2-treated group
in the diencephalon was significantly increased com-
pared to that of the 3xTg-AD group (P < 0.05).
bvPLA2 reduces neuroinflammatory responses in the
hippocampi of the 3xTg-AD mice
To determine whether the neuroprotective effects of
bvPLA2 resulted from the inhibition of microglial activa-
tion in the hippocampus, immunostaining of brain sec-
tions anti-CD11b was performed (Fig. 4). In the WT
group, only a few CD11b+ microglia/macrophages with
resting morphologies (i.e., small cell bodies and thin pro-
cesses) were observed in the hippocampi. In contrast,
Table 1 The results of voxel-wise comparisons. The results of
voxel-wise comparisons between the WT and 3xTg datasets (A),
the 3xTg and 3xTg+donepezil datasets (B), and the 3xTg and
3xTg+bvPLA2 1 mg datasets (C)
Group Brain area Coordinates (x, y, z) Cluster size Z value
A Diencephalon (−1, 3, −2) 16940 2.62
B Cortex (0, 1, −3) 2388 1.82
C Diencephalon (−2, 3, 0) 3359 2.15
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numerous CD11b+ microglia/macrophages with acti-
vated morphologies (i.e., larger cell bodies and thick pro-
cesses) were apparent in the hippocampi of the 3xTg AD
group. However, the majority of the CD11b+ microglia/
macrophages in the bvPLA2-treated group had returned
to a resting morphology in the hippocampi.
bvPLA2 reduces the infiltration of CD4+ T cells into the
hippocampi of 3xTg-AD mice
To determine whether bvPLA2 modulated the infiltration
of CD4+ T cells into the hippocampi of the 3xTg-AD mice,
we performed immunostaining of the hippocampi
with an anti-CD4 antibody. The bvPLA2 treatment
(See figure on previous page.)
Fig. 1 The effects bvPLA2 on the body weights and behaviors of the 3xTg mice. The body weight curves for the different groups of experimental animals
were determined (a). WT PBS-treated wild type group, 3xTg 3xTg group, donepezil donepezil-treated 3xTg group, bvPLA2 0.2 bvPLA2 0.2 mg/kg-treated
3xTg group, 3xTg+bvPLA2 bvPLA2 1 mg/kg-treated 3xTg group. The latencies to escape onto the hidden platform in the Morris water maze. The task was
performed for three trials per day over 4 days for the acquisition test (b). Retention performance was tested on fourth day. In the retention test, the mice
received a probe trial in which the platform was removed from the pool (c). The values are presented as the means ± the SEMs. *P< 0.05, **P< 0.01,
compared to the WT group; #P< 0.05, compared to the 3xTg group (repeated-measures ANOVA with and Tukey’s post hoc analyses)
Fig. 2 Effects of bvPLA2 on Aβ deposition in the hippocampi of 6-month-old 3xTg-AD mice. Aβ burdens were detected with immunohistochemical staining
with anti-Aβ antibodies in the hippocampal regions of CA1 (a, c) and CA3 (b, d). The data are shown as the means ± the SEMs; **P < 0.01, ***P < 0.001
compared to the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared to the 3xTg group (repeated-measures ANOVA with Tukey’s post hoc analyses)
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groups exhibited reduced numbers of infiltrating CD4+ T
cells in the hippocampus compared to the 3xTg AD mice
(Fig. 4).
Neuroprotective effects of bvPLA2 are associated with the
modulation of the peripheral immune tolerance of Tregs
To ascertain whether the increase in Tregs caused by
bvPLA2 treatment was directly involved in the Aβ neu-
roprotective actions, the mice received PC61 anti-CD25
mAb to deplete Tregs or normal anti-rat IgG1 as an iso-
type control. PC61 anti-CD25 mAb is generally used to
deplete of Tregs, and this depletion is mediated by the
antibody-dependent cellular-phagocytosis of FcγRIII+
macrophages in vivo [32]. Consistent with our previous
data [33], the injection of the PC61 anti-CD25 mAb re-
sulted in the depletion of over 90 % of the Foxp3+ cells
in the CD4+-gated splenocytes (data not shown). The
brain sections were immunostained with an anti-Aβ
antibody. Aβ burden did not differ following Treg deple-
tion in the 3xTg AD mice, and the neuroprotective ef-
fects of bvPLA2 were abolished in the Treg-depleted
3xTg AD mice (Fig. 5). Neither PC61 anti-CD25 mAb
nor normal anti-rat IgG alone had any effect on Aβ bur-
den in the hippocampus (Fig. 5). Next, we performed
Morris water maze to measure cognition dysfunctions.
The results demonstrated that there were no significant
differences in the latency between bvPLA2 and PBS
group after Treg depletion by PC61 anti-CD25 mAb in-
jections (Fig. 5). These results strongly indicate that the
neuroprotective effects of bvPLA2 were closely associ-
ated with Tregs in the 3xTg AD mice.
Effects of bvPLA2 on CD4+ CD25+ Foxp3+ T cell
populations
To determine whether bvPLA2 possessed immune
tolerance-enhancing activity that was mediated by Treg
induction, T cell sub-populations in splenocytes were an-
alyzed in splenocytes. The percentages of CD4+ CD25+
Foxp3+ T cells in the splenocytes were reduced in the
3xTg AD group compared to the WT group, while CD4+,
CD8+, and total lymphocytes were not altered. Treatment
with bvPLA2 significantly increased the Treg population
without altering the other lymphocytes, which suggests
that bvPLA2 might suppress neuroinflammatory re-
sponses via Treg induction in 3xTg AD mice (Fig. 5).
Discussion
AD is the most common cause of dementia, and this dis-
ease accounts for 60–80 % of all dementia [34]. The
neuropathology of AD includes Aβ plaques and neurofib-
rillary tangles that are accompanied by neuroinflammation
that is characterized by astrocytosis and microgliosis.
Microglia that are attracted to Aβ deposits represent the
primary cellular component that is associated with AD
neuroinflammation [35]. In the present study, we con-
firmed the hypothesis that bvPLA2 improved cognitive
functioning and reduced the accumulation of Aβ deposi-
tions in the brain. Moreover, we demonstrated that the
neuroprotective effects of bvPLA2 were associated with
the suppression of microglial activation and the reduction
of the infiltration of CD4+ T cells in a 3xTg mouse model
of AD. Furthermore, compared to donepezil, bvPLA2 was
similarly or more effective in reducing the majority of the
cognitive and neuroinflammatory responses. Several stud-
ies have suggested that inflammation has a vital role in the
progression of AD because Aβ can activate microglia and
thus initiate an inflammatory response [36]. Additionally,
lymphocyte infiltration might amplify the inflammatory
response and cause more neuronal death [37, 38]. Al-
though there are no clear T cell responses in the brains of
patients with Alzheimer’s disease, understanding T cell re-
sponses and adaptive immunity has become important for
immunotherapy for Alzheimer’s disease [5].
Tregs are pivotal players in the regulation of tolerance
because they dampen harmful autoimmune T cells and
constrain inflammation [39, 40]. Recently, the modulation
Fig. 3 bvPLA2 increases glucose uptake in the brain. a Voxel-wise comparisons between the WT and 3xTg datasets. The brain regions in which
regional FDG uptake in the WT were significantly greater than those in the 3xTg group (diencephalon). b Voxel-wise comparisons between the
3xTg and 3xTg+donepezil groups. Brain regions in which the regional FDG uptakes in the donepezil treatment group were significantly greater
than those in the 3xTg group (cortex). c Voxel-wise comparisons between the 3xTg and 3xTg+bvPLA2 1 mg/kg groups. The brain regions in
which the regional FDG uptakes in the bvPLA2 treatment group were significantly greater than those in the 3xTg group (diencephalon)
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of Tregs has been proposed as a potential therapeutic ap-
proach for neuroinflammation-mediated disorders includ-
ing AD [41].
AD was one of the first neurodegenerative diseases that
were connected to neurotoxic microglial activation [42].
Activated microglia neurotoxicity has gained a strong
foothold in the field of AD research and is a vital contribu-
tor to Aβ accumulation because activated microglia can
secrete diverse inflammatory molecules, such as IL-1, IL-
6, IFN-γ, TNF-α, and free radicals, which are that are all
associated with Aβ cascade during the occurrence and
progression of AD [43, 44]. Consistently, our results show
that microglial activation was increased in the 3xTg-AD
mice. Moreover, the microglial activation in 3xTg-AD
mice was significantly decreased by bvPLA2 treatment.
CD4+ T cells are involved in various pathological CNS
conditions. CD4+ T cell-mediated autoimmune responses
are crucial in the pathogenesis of multiple sclerosis and, to
some extent, AD [45, 46]. A number of reports further
suggest that T cells are activated in AD patients and that
these cells exist both in the periphery and as infiltrates in
the brain [46]. Our results demonstrated that CD4+ T cell
infiltration into the hippocampus was also dramatically re-
duced by bvPLA2 treatment.
Tregs comprise 5 to 10 % of the peripheral CD4+ T
cells [47, 48]. Increasing evidence has shown that Tregs
exert neuroprotective activities via the suppression of
microglia; these activities have been verified in two inde-
pendent experimental paradigms; i.e., antibody-mediated
Treg depletion [49] and adoptive transfer of Tregs [50].
Although there are many evidences that Treg has benefi-
cial roles in some neurodegenerative diseases, there are
few studies about the roles of Treg in AD. However,
Subramanian et al. showed that the consistently reduced
expression of Foxp3 in spleens from both young and old
3xTg-AD mice compared with normal mice [51]. Treg
decrease was reported in AD patients’ PBMC [52].
In our previous report, we showed that bvPLA2 treat-
ment significantly increased the population of Treg
cells via CD206 receptor on dendritic cells. bvPLA2
was directly bound to CD206, and the increase the
population of Treg cells by bvPLA2 was abolished in
CD206 KO mice [53]. In the present study, we demon-
strated that bvPLA2 was not neuroprotective in Treg-
depleted mice using anti-CD25 antibody injections.
These data indicated the possible involvement of Tregs
in the effects of bvPLA2 that decrease microglial
responses and protect against the accumulation of Aβ
in the 3xTg-AD mouse.
There are two ways of Treg depletion. One way is
using depletion of regulatory T cells (DEREG) mouse ex-
presses a fusion protein of the human diphtheria toxin
(DT) receptor (hDTR) and enhanced green fluorescent
protein (eGFP) under control of the Foxp3 promoter
[54]. Lahl et al. reported that ablation of Foxp3+ T reg
cells in newborn DEREG mice led to the development of
scurfy-like symptoms with splenomegaly, lymphadenop-
athy, insulitis, and severe skin inflammation [55]. Deple-
tion of FOXP3+ Treg cells in 8- to 10-week-old DEREG
promotes hypercholesterolemia and atherosclerosis [54].
The other way of Treg depletion is using antibody tar-
geting the interleukin-2 (IL-2) receptor α-chain (CD25)
on the surface of T cells. CD25+ Treg depletion by PC61
monoclonal antibody induced organ-specific autoimmune
diseases [56], [57]. It has known that the phenotypes of
Foxp3+ Treg-depleted mice and CD25+ Treg-depleted
mice are not exactly same. In our study, we could not
observe any significantly different phenotypes from Treg-
depleted mouse using PC61 antibody.
In recent years, several types of genetically modified
mice have been generated as potential models for studying
neuroinflammation [58], such as the APP/PS1-KO mice
reported by Weitz et al. [58] and the TgSwDI mice re-
ported by Goñi et al. [59]. In the present study, we chose a
triple-transgenic mouse model of AD. The 3xTg-AD
mouse was recently created and harbors three disease-
relevant genetic alterations; i.e., a human presenilin
M146V knock-in mutation (PS1M146V), a human amyl-
oid precursor protein Swedish mutation (APPswe), and
the human tauP301L mutation. These mice develop pla-
ques and tangles in a spatially and temporally dependent
manner that is similar to pathological hallmarks that are
observed in the brains of AD-afflicted individuals [15, 60].
Most conspicuously, this animal model is the first that
was developed to facilitate the study of inflammation in
the context of amyloid pathology. Cognitive impairment is
present in 2-month-old 3xTg-AD mice [61], and Aβ de-
posits in the hippocampus and cortex have been detected
in 6-month-old 3xTg-AD mice [17], which contrasts with
other genetic AD models. These findings indicate that the
pathological features of the 3xTg-AD mice that mimic AD
remain stable. Classic and well-known symptoms of AD
include problems with spatial learning and the presence of
memory deficits.
(See figure on previous page.)
Fig. 4 bvPLA2 reduces neuroinflammatory responses and the infiltration of CD4+ T cells into the hippocampi of 3xTg-AD mice. Treatment with bvPLA2
induced microglial deactivation in the hippocampal CA1 (a, e) and CA3 regions (b, f). Treatment with bvPLA2 induced reductions in CD4+ T cell
infiltration in the hippocampal CA1 (c, g) and CA3 regions (d, h). The representative immunostained cells were indicated as arrows (a–d). The error bars
indicate the SEMs. **P < 0.01, ***P < 0.001 compared to the WT groups; #P < 0.05, ##P < 0.01 compared to the 3xTg group (one-way ANOVA with
Tukey’s post hoc analyses)
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Many epidemiological and functional neuroimaging
[62] studies have shown that the dysregulation of energy
metabolism in the brain is a significant causative factor
in the development of dementia. Positron emission tom-
ography (PET) imaging is a new scanning technique in
medical research. [F-18] FDG micro-PET scanning re-
cently became available for visualizing brain activity in
small rodents [63, 64]. The present study used PET ana-
lyses to demonstrate that the cerebral glucose metabol-
ism of the bvPLA2 dataset was considerably increased in
the brain compared to that of the 3xTg AD mice. Thus,
an important point of our study is that, despite the lim-
ited spatial resolution of the micro-PET system, we were
able to detect focal changes in the brains of the 3xTg-
AD mice. Donepezil is able to ameliorate cognitive defi-
cits, and comparison of this effect to our results leads us
to suggest that the potency of bvPLA2 appears to be
comparable to that of donepezil. Although donepezil is
promising, it has serious side effects that might outweigh
its benefits [13]. The results of others and our own have
revealed that, unlike bvPLA2, donepezil consistently in-
duces major side effects and weight loss [65].
Conclusions
Treatment with bvPLA2 attenuated learning and mem-
ory deficits exerted anti-neuroinflammation effects in
3xTg-AD mice. Based on the results of the present
study, we conclude that bvPLA2 has potential for use in
the treatment of AD.
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